Short Interest in Avenue Therapeutics, Inc. (NASDAQ:ATXI) Drops By 14.3%

Avenue Therapeutics, Inc. (NASDAQ:ATXI) saw a large drop in short interest in the month of June. As of June 15th, there was short interest totalling 42,400 shares, a drop of 14.3% from the May 31st total of 49,500 shares. Approximately 4.9% of the company’s stock are short sold. Based on an average daily trading volume, of 60,600 shares, the short-interest ratio is currently 0.7 days.

Avenue Therapeutics Stock Performance

Avenue Therapeutics stock opened at $3.50 on Monday. Avenue Therapeutics has a 12 month low of $3.25 and a 12 month high of $93.75. The company’s fifty day simple moving average is $4.27 and its 200-day simple moving average is $9.00.

Avenue Therapeutics (NASDAQ:ATXI) last issued its earnings results on Wednesday, May 15th. The company reported ($15.40) earnings per share for the quarter.

About Avenue Therapeutics

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.